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An Exciting First Step Toward a New Therapy?*Nicholas Paivanas, MD, John Bisognano, MD, PHDSEE PAGE 313H ypertension is a highly prevalent conditionand, when untreated, has myriad devas-tating consequences including myocardial
infarction, cardiomyopathy, renal failure, and stroke.
Extensive clinical data support the treatment of hy-
pertension and demonstrates the reduction in cardio-
vascular events, stroke, and death in patients with
hypertension whose blood pressure is controlled (1).
Despite optimal medication management (concurrent
use of 3 different medications of different classes, at
maximally tolerated doses, 1 of which is a diuretic
agent) and ruling out secondary causes of hyperten-
sion, up to 20% to 30% of patients with hypertension
continue to have elevated blood pressure and are
deﬁned as having treatment-resistant hypertension.
These patients are at a 3-fold increased risk of adverse
cardiovascular outcomes compared with those with
treatment-responsive hypertension (2). It is this sub-
group of patients in whom additional therapies are
needed to successfully control their hypertension
and to reduce their risk of major adverse events. Only
recently has the medical community begun to fully
embrace that this population requires a special focus
that goes beyond simple medical adherence, medica-
tion selection, and life-style modiﬁcation approaches
and that the cost of their comorbidites, both personal
and ﬁnancial, warrant the development of new
approaches.*Editorials published in JACC: Basic to Translational Science reﬂect the
views of the authors and do not necessarily represent the views of JACC:
Basic to Translational Science or the American College of Cardiology.
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the contents of this paper to disclose.In this issue of the JACC: Basic to Translational
Science, Narkiewicz et al. (3) report the results of a
proof-of-concept study of unilateral carotid body
resection in patients with treatment-resistant hyper-
tension. A total of 15 patients with ofﬁce blood pres-
sures of 179  7/106  4 mm Hg on 5.7  0.3
antihypertensive drugs were included in the trial and
were followed for 12 months after unilateral carotid
body resection. Successful carotid body resection was
deﬁned as pathological evidence of glomus cells in
resected tissue, and this was conﬁrmed in 14 of the 15
patients. Patients were monitored for changes in
hypoxic ventilatory response, polysomnography,muscle sympathetic nerve activity, blood pressure,
and general adverse events. A total of 8 of the 14
patients with successful carotid body excision were
found to be responders to the procedure, as evi-
denced by reduction in muscle sympathetic nerve
activity and >10 mm Hg drop in ambulatory blood
pressure at 3- and 6-month follow-up. Serious
adverse events included 1 patient with pre-existing
sleep apnea who had worsening of the apnea-
hypopnea index, and 1 patient who was hospitalized
after the procedure with difﬁcult-to-control blood
pressure. The procedure was otherwise deemed to be
safe.
Resection of the carotid body aims to decrease
blood pressure through reduction in afferent sympa-
thetic tone originating from signals in the carotid
body. In contrast, baroreﬂex activation therapy
(BAT) stimulates the baroreﬂex, which subsequently
leads to a decrease in sympathetic tone and increase
in vagal tone. BAT has been studied most exten-
sively in humans via implantation of an electrical
stimulator (Rheos and Barostim Neo devices, CVRX,
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326Minneapolis, Minnesota) (4) and is also being tar-
geted through dynamic shape change of the carotid
sinus by a new stent (MobiusHD, Vascular Dynamics,
Mountain View, California). BAT via electrical stim-
ulation involves placement of a pacemaker-like
generator under the skin in the chest and then
tunneling a lead to the carotid sinus. An early device
(Rheos) involved placement of a lead with 4 ﬁnger-
like electrodes on each carotid bulb and wrapping
these electrodes around the bilateral carotid bulbs. A
newer device (Barostim Neo) involves a simpler
placement of a single lead with a single electrode on a
unilateral carotid bulb. BAT has started to accrue
signiﬁcant trial data to date and has 5-year follow-up
data published, which continues to be promising. The
procedure is generally well tolerated, although the
earlier Rheos device carried a periprocedural event
rate similar to open carotid endarterectomy. In
contrast, the novel carotid sinus MobiusHD stent in-
volves placement of an endovascular stent via
percutaneous approach. The stent then induces a
dynamic shape change in the carotid sinus leading to
activation of the baroreﬂex. Although trial data have
not yet been completed for the MobiusHD stent
(CALM-FIM_US [Controlling and Lowering Blood
Pressure With The MOBIUSHD], NCT01831895), it is
appealing in its potential to have a less-invasive
approach to activating the carotid baroreﬂex.
With regard to efﬁcacy of unilateral versus bilateral
therapy, baroreﬂex activation therapy was initially
utilized by stimulating the bilateral carotid bulbs, but
a subsequent device (Barostim Neo) applied stimula-
tion only to a unilateral carotid body and achieved
similar physiological effects; presumably, the same
feedback mechanism affects the bilateral barorecep-
tors. It will be interesting to track the response of
unilateral carotid body excision and determine
whether the contralateral carotid body over extended
time fully assumes the prior efﬁcacy of both carotid
bulbs or whether the fall in blood pressure remains
durable. The dramatic fall in both ofﬁce and ambu-
latory blood pressure seen in responders in the ﬁrst
months after surgery seems to attenuate at the
12-month follow-up in the current study, and further
follow-up with more patients is certainly warranted.
Although more anatomically distant, renal sympa-
thectomy also draws parallels with carotid body
resection. In both, reduction in blood pressure is
achieved through the reduction in sympathetic
outﬂow through surgical removal of a stimulating
region. Surgical renal sympathetic denervation was
reported in humans dating back to the 1930s.
Although it resulted in some impressive reductions
in blood pressure, procedural morbidity and increasedmedication options led to its abandonment.
More recently, percutaneous renal sympathetic
denervation has been studied with the Simplicity
catheter system (Medtronic, Minneapolis, Minnesota)
(5). With it, radiofrequency ablation is applied to the
renal sympathetics via the renal artery. Initial positive
results and minimal morbidity with this procedure led
to much enthusiasm, which subsequently waned after
a large prospective randomized trial of more than 500
patients failed to show signiﬁcant efﬁcacy in reduc-
tion of blood pressure compared with the control
group (5). Whether the lack of efﬁcacy was due to
insufﬁcient ablation of the renal sympathetics (sug-
gesting a change in the technical aspect of the proce-
dure could lead to more success) or whether renal
denervation does not truly result in signiﬁcant dura-
ble blood pressure change is not entirely clear.
Nevertheless, applying a similar catheter-based abla-
tion to the carotid body instead of surgical excision is
another potential source of research. Although
catheter-based treatment has an inherent appeal over
surgery due to its less invasive nature, the lessons
from catheter-based renal denervation give reason to
ensure that catheter-based procedures can sufﬁ-
ciently match the efﬁcacy of open surgery in terms of
target tissue affected as well as clinical outcomes.
Compared with other procedural approaches to
reducing hypertension via alteration in nervous sys-
tem signaling, carotid body resection represents a
novel approach. Surgical removal is an inherently
permanent, nonpharmacological intervention that
does not require placement of a foreign object in the
patient. Although this has advantages of inherent
compliance and removes the usual concerns with
device implantation such as infection and device
failure, it also has the disadvantage of being irre-
versible and requiring a signiﬁcant surgical proce-
dure. It is as yet unclear whether, in the event of
severe hemodynamic stress, a patient would retain
the capability to mount an appropriate response.
Although the authors demonstrated glomus cells in
resected tissue, it is also possible that only partial
resection was achieved in some patients. Whether
this makes a clinically signiﬁcant difference in the
rate of patients responding to treatment is not
known.
In summary, Narkiewicz et al. (3) have nicely
demonstrated the feasibility of a novel technique for
surgical removal of the carotid body. Although not
powered for efﬁcacy, the results of this proof-of-
concept study show a deﬁnite trend toward blood
pressure lowering in patients who responded to the
treatment. With the increasing recognition of the
importance of treatment of resistant hypertension,
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327this demonstrates an interesting target for future
nonpharmacological therapies. Whether these thera-
pies are surgical excision, catheter-based ablation, or
permanent device implantation remains to be seen,
and it would be wonderful to see each of these pro-
cedures developed to yield efﬁcacy for the wide va-
riety of patients with this disease. Now that this
technique is proven feasible, follow-up studies with
larger numbers of patients will be needed to assess
the efﬁcacy and also hopefully determine which pa-
tients will respond signiﬁcantly to the therapy. The
authors’ observation of elevated hypoxic ventilator
response and respiratory frequency in responders
suggest that this might be a fruitful tool for identi-
fying patients who will be more likely to respond to
the therapy before undergoing a procedure. Ideally,
with additional research in this ﬁeld, clinicians will
have the tools to identify patients who are appro-
priate for a nonpharmacological intervention andwill be able to select between multiple procedures
to tailor appropriate interventions to a given
patient before he or she undergoes a procedure.
Although controlling hypertension with a few easily
tolerated and inexpensive medications beneﬁts a
large majority of patients, the continued high burden
of myocardial infarction, heart failure, and stroke
in patients with treatment-resistant hypertension
shines a light on the need to continue to develop new
treatments for this disease. Evolving invasive ap-
proaches to hypertension management, such as ca-
rotid body resection, offer an exciting potential to ﬁll
this need.
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